Healthcare / BiotechnologyNasdaqCM
$2.64
-0.15 (-5.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.7M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-223.6%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-33.6M · FCF $-22.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Net Income | $-33.6M | $-33.6M | $-26.0M | $-29.8M | $-29.0M | $-15.9M | $-17.4M | $-13.2M | $-11.9M | $-9.8M | $-3.9M | — |
| EBITDA | $-25.0M | $-25.0M | $-26.5M | $-29.5M | $-30.5M | $-22.8M | $-19.5M | $-17.3M | $-15.0M | $-8.6M | $-3.9M | — |
| EPS | -28.42 | -28.42 | -189.14 | -376.75 | -378.75 | -221.25 | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.02 | 0.01 | — | — | — | — | — | — | — |
| Current Ratio | 1.38 | 1.38 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-22.7M | $-22.7M | $-23.9M | $-23.7M | $-27.7M | $-19.0M | $-18.1M | $-17.3M | $-12.6M | $-7.4M | $-3.8M | — |
| Returns | ||||||||||||
| ROE | -223.6% | -223.6% | -232.4% | -114.2% | -55.6% | -20.1% | -97.7% | -84.8% | -83.2% | -57.3% | -26.2% | — |
| Valuation | ||||||||||||
| P/B | 0.21 | 0.21 | 0.55 | 0.95 | 0.66 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| EPS Growth | 85.0% | 85.0% | 49.8% | 0.5% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-87.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-189.14 → -28.42
Residual
-87.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.